<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183442</url>
  </required_header>
  <id_info>
    <org_study_id>ENM-DA012</org_study_id>
    <nct_id>NCT01183442</nct_id>
  </id_info>
  <brief_title>Vitamin D Supplementation in CAD and Postchallenge Hyperglycemia</brief_title>
  <official_title>Effects of Vitamin D Supplementation in Coronary Artery Disease Patients With Postchallenge Hyperglycemia and Vitamin D Deficiency on Endothelial Function and Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the investigation is to clarify, whether vitamin D supplementation in&#xD;
      coronary artery disease patients with vitamin D deficiency and postchallenge hyperglycemia&#xD;
      has an impact on endothelial dysfunction and parameters of insulin sensitivity and beta-cell&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An improvement of endothelial dysfunction as a cardiovascular surrogate parameter could be&#xD;
      translated in a reduced risk for future cardiovascular events, which is of major interest,&#xD;
      since patients with postchallenge hyperglycemia face a significantly higher cardiovascular&#xD;
      risk than patients with normal glucose tolerance. Furthermore an improvement in insulin&#xD;
      sensitivity and/or beta-cell function would identify vitamin D as an important strategy for&#xD;
      the prevention of type 2 diabetes. In consideration of the rapidly increasing prevalence of&#xD;
      diabetes and the failure of current prevention strategies this could be an important, safe&#xD;
      and cheap way to support ongoing lifestyle modifying programs. Our study of course&#xD;
      investigates surrogate cardiovascular and insulin sensitivity parameters. Assuming a&#xD;
      beneficial effect of vitamin D in our study, this concept would have to be proven in further&#xD;
      large outcome as well as diabetes prevention trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    unable to recruit&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial dysfunction</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in endothelial dysfunction (peripheral artery tone (PAT) and biochemical)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin resistance and beta-cell function</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in indices for insulin resistance and beta-cell function</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Postprandial Hyperglycemia</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>vitamin D (Oleovit®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vitamin D drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin D</intervention_name>
    <description>orally administered 2800 IU of vitamin D or placebo daily</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>vitamin D (Oleovit®)</arm_group_label>
    <other_name>vitamin d (Oleovit®)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 40-75&#xD;
&#xD;
          -  Postchallenge hyperglycemia (2h-whole blood glucose value in oral glucose tolerance&#xD;
             test above 119 mg/dl, normal fasting glucose)&#xD;
&#xD;
          -  Angiographically verified coronary artery disease (&gt;50% stenosis)&#xD;
&#xD;
          -  Serum 25-OH- vitamin D &lt; 20 ng/ml in winter/spring/autumn and &lt;25 ng/ml during&#xD;
             june-september&#xD;
&#xD;
          -  Stable antihypertensive therapy in the last 3 month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute coronary syndrome or cerebrovascular event within the previous 1 month&#xD;
&#xD;
          -  BMI &gt; 40 kg/m²&#xD;
&#xD;
          -  Serum creatinine &gt;2.5 times the upper limit of normal&#xD;
&#xD;
          -  GOT or GPT &gt; 3 times the upper limit of normal&#xD;
&#xD;
          -  Heart failure &gt; NYHA class II&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt;160/100 mmHg)&#xD;
&#xD;
          -  New onset of statins, ACE-inhibitors or ARBs within the previous 4 weeks&#xD;
&#xD;
          -  History of urolithiasis&#xD;
&#xD;
          -  Hypercalcaemia&#xD;
&#xD;
          -  Major psychiatric disorders&#xD;
&#xD;
          -  Ongoing treatment with spironolactone, canrenoate, eplerenone, amiloride, triamterene&#xD;
             and aliskiren.&#xD;
&#xD;
          -  Treatment with antipsychotic drugs&#xD;
&#xD;
          -  Regular significant antioxidants, vitamins or protein supplementation&#xD;
&#xD;
          -  Immunosuppressive therapy&#xD;
&#xD;
          -  Glucocorticoid therapy&#xD;
&#xD;
          -  Ongoing chemotherapy&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any other disease with an estimated life expectancy below 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas R. Pieber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Graz, Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Internal Medicine, Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <last_update_submitted>April 16, 2015</last_update_submitted>
  <last_update_submitted_qc>April 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

